What is CORE Diagnostics?
CORE Diagnostics operates as a premier diagnostic center and pathology laboratory, specializing in high-complexity testing for oncology, reproductive health, and inherited diseases. By integrating advanced molecular biology and cytopathology into its service model, the company provides essential diagnostic clarity that informs critical clinical decision-making. Its market position is characterized by a focus on high-end, innovative testing solutions that bridge the gap between complex laboratory science and accessible patient care. Through its network of facilities, the organization serves as a vital partner to the medical community, ensuring that precise diagnostic data is available to improve patient prognosis and treatment efficacy.
How much funding has CORE Diagnostics raised?
CORE Diagnostics has raised a total of $17.3M across 2 funding rounds:
Series A
$5M
Series B
$12.3M
Series A (2012): $5M with participation from Artiman Ventures
Series B (2016): $12.3M led by Artiman Ventures, F-Prime Capital Partners, and Eight Roads Ventures
Key Investors in CORE Diagnostics
Artiman Ventures
Artiman Management LLC is an investment firm that focuses on innovative companies in various sectors, with a specific interest in healthcare and diagnostic platforms that leverage technology to improve clinical outcomes.
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
Eight Roads Ventures
Eight Roads Ventures is a global venture capital firm that backs technology and healthcare companies, providing the strategic support necessary for scaling operations in complex markets.
What's next for CORE Diagnostics?
With the support of its latest strategic financing, CORE Diagnostics is well-positioned to expand its footprint in the competitive diagnostic market. The company is expected to prioritize the scaling of its proprietary testing platforms and the integration of next-generation sequencing technologies to maintain its competitive edge. Future strategic initiatives will likely focus on deepening its penetration into specialized diagnostic segments, such as precision oncology and personalized medicine, while optimizing operational efficiencies across its laboratory network. By maintaining a focus on high-value diagnostic services, the firm is poised to capitalize on the increasing demand for reliable, data-driven healthcare solutions in India and beyond.
See full CORE Diagnostics company page
